– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14%.
Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.
Dr Phillips on Treatment With Bispecific Antibodies and CAR T-Cell Therapy in MCL onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.